121 related articles for article (PubMed ID: 9472847)
1. Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer's disease.
Grothe DR; Piscitelli SC; Dukoff R; Fullerton T; Sunderland T; Molchan SE
J Clin Psychopharmacol; 1998 Feb; 18(1):78-81. PubMed ID: 9472847
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of drugs for Alzheimer's disease.
Parnetti L
Clin Pharmacokinet; 1995 Aug; 29(2):110-29. PubMed ID: 7586900
[TBL] [Abstract][Full Text] [Related]
3. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy.
Laine K; Palovaara S; Tapanainen P; Manninen P
Clin Pharmacol Ther; 1999 Dec; 66(6):602-8. PubMed ID: 10613616
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
Roberts CJ; Ford JM; Truman CA; Scott M; Mäkelä PM; Wilcock GK
Eur J Clin Pharmacol; 1998; 54(9-10):721-4. PubMed ID: 9923574
[TBL] [Abstract][Full Text] [Related]
5. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
[TBL] [Abstract][Full Text] [Related]
6. WITHDRAWN: Tacrine for Alzheimer's disease.
Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic studies of cholinesterase inhibitors.
Johansson M; Nordberg A
Acta Neurol Scand Suppl; 1993; 149():22-5. PubMed ID: 8128833
[TBL] [Abstract][Full Text] [Related]
8. Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy.
Valis M; Masopust J; Vysata O; Hort J; Dolezal R; Tomek J; Misik J; Kuca K; Karasova JZ
Neurotox Res; 2017 Jan; 31(1):162-168. PubMed ID: 27718143
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.
Lou G; Montgomery PR; Sitar DS
J Psychiatry Neurosci; 1996 Nov; 21(5):334-9. PubMed ID: 8973053
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease.
Cutler NR; Sedman AJ; Prior P; Underwood BA; Selen A; Balogh L; Kinkel AW; Gracon SI; Gamzu ER
Psychopharmacol Bull; 1990; 26(2):231-4. PubMed ID: 2236461
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
12. Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.
Ahlin A; Hassan M; Junthé T; Nybäck H
Int Clin Psychopharmacol; 1994; 9(4):263-70. PubMed ID: 7868848
[TBL] [Abstract][Full Text] [Related]
13. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
Schneider LS; Farlow MR; Henderson VW; Pogoda JM
Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients.
Johansson M; Hellström-Lindahl E; Nordberg A
Dementia; 1996; 7(2):111-7. PubMed ID: 8866685
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine.
Basun H; Nilsberth C; Eckman C; Lannfelt L; Younkin S
Dement Geriatr Cogn Disord; 2002; 14(3):156-60. PubMed ID: 12218259
[TBL] [Abstract][Full Text] [Related]
16. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease.
Ford JM; Truman CA; Wilcock GK; Roberts CJ
Clin Pharmacol Ther; 1993 Jun; 53(6):691-5. PubMed ID: 8513661
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Schneider L; Hui SL
Neurology; 1998 Mar; 50(3):669-77. PubMed ID: 9521254
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
Gutzmann H; Kühl KP; Hadler D; Rapp MA
Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
[TBL] [Abstract][Full Text] [Related]
19. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Nordberg A; Svensson AL
Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.
Cutler NR; Polinsky RJ; Sramek JJ; Enz A; Jhee SS; Mancione L; Hourani J; Zolnouni P
Acta Neurol Scand; 1998 Apr; 97(4):244-50. PubMed ID: 9576639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
